StockData
Northwest Biotherapeutics Inc logo

Northwest Biotherapeutics Inc (NWBO) stock

NWBOOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.16−0.00 (-0.88%)

Close on Oct 19, 2026Market cap $254.79MP/E –Yield –

Northwest Biotherapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Northwest Biotherapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$47.61M. For fiscal 2025 it was -$57.85M. The highest annual figure on record is -$15.35M in fiscal 2010.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$57.85M–
FY2024Dec 31, 2024-$64.76M–
FY2023Dec 31, 2023-$53.98M–
FY2022Dec 31, 2022-$65.93M–
FY2021Dec 31, 2021-$52.38M–
FY2020Dec 31, 2020-$86.52M–
FY2019Dec 31, 2019-$27.96M–
FY2018Dec 31, 2018-$40.19M–
FY2017Dec 31, 2017-$54.24M–
FY2016Dec 31, 2016-$79.08M–
FY2015Dec 31, 2015-$126.23M–
FY2014Dec 31, 2014-$101.13M–
FY2013Dec 31, 2013-$55.46M–
FY2012Dec 31, 2012-$43.81M–
FY2011Dec 31, 2011-$26.78M–
FY2010Dec 31, 2010-$15.35M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$10.83M–
Q1 FY2026Mar 31, 2026-$10.13M–
Q4 FY2025Dec 31, 2025-$12.74M–
Q3 FY2025Sep 30, 2025-$13.91M–
Q2 FY2025Jun 30, 2025-$14.33M–
Q1 FY2025Mar 31, 2025-$16.88M–
Q4 FY2024Dec 31, 2024-$18.06M–
Q3 FY2024Sep 30, 2024-$14.40M–
Q2 FY2024Jun 30, 2024-$16.96M–
Q1 FY2024Mar 31, 2024-$15.34M–
Q4 FY2023Dec 31, 2023-$14.72M–
Q3 FY2023Sep 30, 2023-$13.41M–
Q2 FY2023Jun 30, 2023-$13.23M–
Q1 FY2023Mar 31, 2023-$12.63M–
Q4 FY2022Dec 31, 2022-$17.86M–
Q3 FY2022Sep 30, 2022-$15.31M–
Q2 FY2022Jun 30, 2022-$20.58M–
Q1 FY2022Mar 31, 2022-$12.19M–
Q4 FY2021Dec 31, 2021-$10.59M–
Q3 FY2021Sep 30, 2021-$9.95M–
Q4 FY2020Dec 31, 2020-$23.31M–
Q3 FY2020Sep 30, 2020-$47.86M–
Q2 FY2020Jun 30, 2020-$7.53M–
Q1 FY2020Mar 31, 2020-$7.82M–
Q4 FY2019Dec 31, 2019-$6.73M–
Q3 FY2019Sep 30, 2019-$6.58M–
Q2 FY2019Jun 30, 2019-$6.63M–
Q1 FY2019Mar 31, 2019-$7.76M–
Q4 FY2018Dec 31, 2018-$2.76M–
Q3 FY2018Sep 30, 2018-$8.98M–
Q2 FY2018Jun 30, 2018-$20.00M–
Q1 FY2018Mar 31, 2018-$8.45M–
Q4 FY2017Dec 31, 2017-$17.68M–
Q4 FY2016Dec 31, 2016-$21.19M–
Q3 FY2016Sep 30, 2016-$25.46M–
Q2 FY2016Jun 30, 2016-$14.96M–
Q1 FY2016Mar 31, 2016-$17.47M–
Q4 FY2015Dec 31, 2015-$51.37M–

More Northwest Biotherapeutics figures

See a number that looks wrong?